Lightnews — Scholar-powered news

Francesco Bertoni @frbertoni.bsky.social · 7d

Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch

onlinelibrary.wiley.com/doi/10.1111/...

Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma

Click on the article title to read more.

onlinelibrary.wiley.com

Francesco Bertoni @frbertoni.bsky.social · 13d

The review article, written in collaboration with Camille Laurent, on the biology of marginal zone lymphomas is now published in Blood. @iorbellinzona.bsky.social @usi.ch Università della Svizzera italiana @snsf.ch

doi.org/10.1182/bloo...

The Biology of MZL subtypes: Challenge and Relevance of Classification

Marginal zone lymphomas (MZLs) are a heterogeneous group of low-grade B-cell neoplasms classified into different entities by the current lymphoma classific

doi.org

3

Francesco Bertoni @frbertoni.bsky.social · 22d

“Recent Advances in Treating Diffuse Large B-Cell Lymphoma “ by Jim Armitage
ascopost.com/issues/june-...

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...

ascopost.com

Francesco Bertoni @frbertoni.bsky.social · 24d

A work, by Filippo Spriano in our lab, exploring the mechanisms of resistance to TK216, a molecule that targets ETS factors, is now available in bioRxiv

www.biorxiv.org/content/10.1...

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implica...

www.biorxiv.org

1

Francesco Bertoni @frbertoni.bsky.social · 26d

Our collaborative work with Sebastian Patzke and Jostein Dahle on the CD37 targetting radioimmunoconjugated antibody 177Lu-lilotomab satetraxetan (Betalutin) is out in the British Journal of Haematology.
onlinelibrary.wiley.com/doi/10.1111/...

onlinelibrary.wiley.com

Francesco Bertoni @frbertoni.bsky.social · 27d

Thanks to a collaboration with Francesco Buonocore and Maria Luisa Mangoni, we explored antimicrobial peptides (AMPs) in marginal zone lymphomas. The initial work by Filippo Spriano and others at the @iorbellinzona.bsky.social, is now available. @usi.ch
www.biorxiv.org/content/10.1...

Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies

Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptid...

www.biorxiv.org

4

Francesco Bertoni @frbertoni.bsky.social · Sep 13

A screening of the Irish marine biorepository identified a new bryostatin analog active in lymphomas. Nice collaboration with Olivier Thomas, his team, Filippo Spriano and other members of our @iorbellinzona.bsky.social lab. @usi.ch @sib.swiss
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...

Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma

Bryostatin analogs are found to be accumulated in the nudibranch Antiopella cristata collected in Irish waters. These are found to be potent inhibitors of activated B-cells diffuse large B-cell lymph....

chemistry-europe.onlinelibrary.wiley.com

3

Francesco Bertoni @frbertoni.bsky.social · Sep 12

Registrations are open for the next LyFE - Lymphoma Forum of Excellence
«What's new in lymphoid neoplasias?», Bellinzona, Switzerland, February 2026
www.lymphomaforum.ch

Home

www.lymphomaforum.ch

1

Reposted by Francesco Bertoni

Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · Sep 9

#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.

Learn more: tinyurl.com/ytybcbr8

1 2

Francesco Bertoni @frbertoni.bsky.social · Aug 29

Project Hail Mary by Andy Weir: a very nice reading!
en.wikipedia.org/wiki/Project...

Project Hail Mary - Wikipedia

en.wikipedia.org

1

Francesco Bertoni @frbertoni.bsky.social · Aug 7

Elliott Smith - www.udiscovermusic.com/stories/best...

Best Elliott Smith Songs: 20 Essential Tracks

The best Elliott Smith songs reflect his ability to wring beauty out of life’s traumas. His prolific output still endures.

www.udiscovermusic.com

2

Reposted by Francesco Bertoni

ESMO - European Society for Medical Oncology @myesmo.bsky.social · Aug 5

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c

3 7

Francesco Bertoni @frbertoni.bsky.social · Aug 5

new ESMO Lymphoma Clinical Practice Guideline for diagnosis, treatment and follow-up
www.esmo.org/guidelines/e...

www.esmo.org

3

Reposted by Francesco Bertoni

Pedro Friedmann Angeli @angelifriedmann.bsky.social · Aug 4

A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.

If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.

pls share 🙏

5 5

Reposted by Francesco Bertoni

TingTing Zhang @tingtingzhang.bsky.social · Aug 3

Here is a curated list of #patienteducation resources in Simplified or Traditional #Chinese on #health- or #cancer- related topics available from US, UK, EU, Australia, Singapore, Hong Kong, Taiwan, and India. We are curating support groups in US - input needed

blogs.hear2care.org/patientresou...

中文漢語醫患資訊 – blogs.hear2care.org

blogs.hear2care.org

3 3

Francesco Bertoni @frbertoni.bsky.social · Aug 2

“The Best Song From Every David #Bowie Album” by Ultimate Classic Rock: I largely agree but I would have chosen differently from some album. Difficult sometime to select only one song. Bowie is still the best one.

ultimateclassicrock.com/david-bowie-...

David Bowie's Best Song From Each of His Albums

David Bowie's career reflects a rich evolution in music and persona, showcasing his vast influence across genres from rock to jazz.

ultimateclassicrock.com

2

Francesco Bertoni @frbertoni.bsky.social · Jul 27

Sonic Youth’s Daydream Nation amazed when they came out and I still listen to it. Wonderful album and band.

www.udiscovermusic.com/stories/soni...

The Best Sonic Youth Songs: Alternative Classics

Such is the consistency and variety of their extensive catalogue, it's almost impossible to make a definitive best Sonic Youth songs list.

www.udiscovermusic.com

1

Francesco Bertoni @frbertoni.bsky.social · Jul 24

Slash’s 10 greatest riffs ever

faroutmagazine.co.uk/slash-10-gre...

The 10 greatest riffs of Slash's life

Slash is one of the most exciting and versatile guitarists in the world, and these top ten riffs prove exactly why that's the case.

faroutmagazine.co.uk

1

Francesco Bertoni @frbertoni.bsky.social · Jul 21

Circulating miRNA in lymphomas. The work by Giulia Regazzo from Maria Giulio Rizzo’s group in Rome is out in the BJH. Glad to have contributed. @iorbellinzona.bsky.social @usi.ch

onlinelibrary.wiley.com/doi/10.1111/...

onlinelibrary.wiley.com

1

Francesco Bertoni @frbertoni.bsky.social · Jul 21

faroutmagazine.co.uk/jimi-hendrix...

The Jimi Hendrix song that perfected the wah-wah pedal

A look at the wah-wah pedal, its history and how Jimi Hendrix perfected its use in one of his best-known and best-loved songs.

faroutmagazine.co.uk

2

Francesco Bertoni @frbertoni.bsky.social · Jul 15

Our very interesting work on CXCR4 inhibition to increase the activity of therapies in B-cell lymphomas is now available in bioRxiv. Thanks to Laura Barnabei, Alberto Arribas, and all the contributors. @iorbellinzona.bsky.social @sib.swiss @usi.ch

www.biorxiv.org/content/10.1...

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models

Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various ...

www.biorxiv.org

Francesco Bertoni @frbertoni.bsky.social · Jul 10

I have never watched Doctor Who, but I alway listen to Lee Scratch Perry🙂

1

Reposted by Francesco Bertoni

Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · Jul 5

Registration is open for the International Prostate Cancer Symposium (IPCS) 28–29 April 2026 – Lugano, Switzerland

Held just before APCCC 2026, IPCS is your chance to explore next-gen treatments & breakthrough research in prostate cancer care.

🔗Register now: apccc.org

1

Reposted by Francesco Bertoni

Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · Jul 4

#IORjobs
IOR invites applications from outstanding candidates interested in applying for the SNSF Ambizione and Marie Skłodowska-Curie Actions (MSCA) and EMBO fellowships.

⏳ IOR internal deadline: 3 August 2025

➡️ Details & application procedure: shorturl.at/caVdu

1 1

Francesco Bertoni @frbertoni.bsky.social · Jul 4

“The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden supporting its ongoing exploration as a [first-line] treatment “
ascopubs.org/doi/10.1200/...

ascopost.com/news/july-20...

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

PURPOSEImproved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients with high burden or...

ascopubs.org

1 2